Corrections to “Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
Year: 2018
Type: erratum
Abstract: Ann Oncol 2013; 24: vi24–vi32 (doi:10.1093/annonc/mdt333) Under the section “Adjuvant chemotherapy for early-stage disease” Long-term follow-up of the ICON 1 trial confirms the benefit of adjuvant chemotherapy, particularly in those patients at higher risk of recurrence (stage 1B/C grade 2/3, any grade 3 or clear-cell histology) [34.Swart A.C. on behalf of ICON collaborators. Long-term follow-up of women enrolled in a randomized trial of adjuvant chemotherapy for early stage ovarian cancer (ICON1).J Clin Oncol (Meeting Abstracts). 2007; 25: Abstr 5509Crossref Google Scholar]. Therefore, adjuvant chemotherapy should be offered not only to suboptimally staged patients but also to those optimally staged at higher risk of recurrence [I, A]. Is replaced with: Long-term follow-up of the ICON 1 trial confirms the benefit of adjuvant chemotherapy, particularly in those patients at higher risk of recurrence [34.Swart A.C. on behalf of ICON collaborators. Long-term follow-up of women enrolled in a randomized trial of adjuvant chemotherapy for early stage ovarian cancer (ICON1).J Clin Oncol (Meeting Abstracts). 2007; 25: Abstr 5509Crossref Google Scholar]. Therefore, adjuvant chemotherapy should be offered not only to suboptimally staged patients but also to stage IB grade 2/3, all stage IC, any grade 3 or clear-cell histology [I, A]. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of OncologyVol. 24PreviewThe estimated number of new ovarian cancer cases in Europe in 2012 was 65 538 with 42 704 deaths [1]. There is variation in the incidence rate across the continent with a higher incidence in northern European countries. In the USA, there were ∼20 400 newly diagnosed cases and 14 400 deaths in 2009 [2]. Ovarian cancer is the fifth most common type of cancer in women and the fourth most common cause of cancer death in women. The estimated lifetime risk for a woman developing ovarian cancer is about 1 in 54. Full-Text PDF Open Archive
Source: Annals of Oncology
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W2999409656